Shandong Xinhua Pharmaceutical (HKG:0719) received the registration certificate for its bisoprolol fumarate tablets from China's National Medical Products Administration, a Monday Hong Kong bourse filing said.
The drug is indicated for the treatment of hypertension, coronary heart disease, and chronic stable heart failure accompanied by decreased left ventricular systolic function.